Phathom Pharmaceuticals, Inc.
PHAT
$10.90
$0.403.81%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3,055.71% | 8,001.47% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,055.71% | 8,001.47% | -- | -- | -- |
| Cost of Revenue | 1,800.67% | 4,674.25% | -- | -- | -- |
| Gross Profit | 3,427.64% | 9,080.39% | -- | -- | -- |
| SG&A Expenses | 100.28% | 146.48% | 195.74% | 137.93% | 62.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.53% | 98.05% | 118.07% | 74.04% | 27.44% |
| Operating Income | -38.22% | -65.84% | -99.84% | -67.47% | -25.87% |
| Income Before Tax | -40.21% | -65.84% | -91.70% | -60.67% | -26.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.21% | -65.84% | -91.70% | -60.67% | -26.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.21% | -65.84% | -91.70% | -60.67% | -26.56% |
| EBIT | -38.22% | -65.84% | -99.84% | -67.47% | -25.87% |
| EBITDA | -38.28% | -65.93% | -100.07% | -67.67% | -25.96% |
| EPS Basic | -18.80% | -37.69% | -48.61% | -16.99% | 9.39% |
| Normalized Basic EPS | -18.80% | -37.69% | -48.61% | -16.99% | 9.39% |
| EPS Diluted | -18.80% | -37.69% | -48.61% | -16.99% | 9.39% |
| Normalized Diluted EPS | -18.80% | -37.69% | -48.61% | -16.99% | 9.39% |
| Average Basic Shares Outstanding | 20.48% | 23.26% | 26.41% | 35.10% | 37.44% |
| Average Diluted Shares Outstanding | 20.48% | 23.26% | 26.41% | 35.10% | 37.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |